PRESS RELEASE published on 05/28/2024 at 19:00, 1 year 8 months ago JTC Team to Host the Virtual Investor Pitch Conference on June 17-18, 2024 JTC Team announces Virtual Investor Pitch Conference on June 17-18, 2024, featuring live video webcast presentations with Q&A. Participating company line-up to be revealed later Investor Relations JTC Team Virtual Investor Pitch Conference Live Video Webcast Q&A
BRIEF published on 05/23/2024 at 16:35, 1 year 8 months ago GRI Bio (NASDAQ : GRI) participe à Virtual Investor CEO Connect Relations Avec Les Investisseurs Communications D'entreprise Biographie Du GRI Investisseur Virtuel Connexion Du PDG
BRIEF published on 05/23/2024 at 16:35, 1 year 8 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect Investor Relations Corporate Communications GRI Bio Virtual Investor CEO Connect
PRESS RELEASE published on 05/23/2024 at 16:30, 1 year 8 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect JTC Team announces CEO Connect segment with GRI Bio's Marc Hertz, PhD, covering recent achievements and upcoming milestones. Virtual Investor platform offers more videos GRI Bio Virtual Investor CEO Connect JTC Team Communication Strategies
BRIEF published on 04/25/2024 at 15:50, 1 year 9 months ago Moleculin Biotech souligne le rôle de l'annamycine dans le traitement de la LMA dans le segment des investisseurs virtuels du JTC Essais Cliniques Opportunité D'investissement Biotechnologie Moléculaire Annamycine Traitement LMA
BRIEF published on 04/25/2024 at 15:50, 1 year 9 months ago Moleculin Biotech Emphasizes Annamycin's Role in AML Treatment in JTC Virtual Investor Segment Clinical Trials Investment Opportunity Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 04/25/2024 at 15:45, 1 year 9 months ago Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team Moleculin CEO highlights Annamycin's differentiation in AML treatment landscape and investment opportunity. Positive interim data shared in 'What This Means' segment Investment Opportunity Clinical Trial Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 10/18/2023 at 16:00, 2 years 4 months ago JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023
Published on 02/20/2026 at 18:30, 18 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 3 hours 3 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 4 hours 18 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 4 hours 40 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 4 hours 48 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 12 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 17 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 48 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 48 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 09:28, 9 hours 20 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026
Published on 02/20/2026 at 09:28, 9 hours 20 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
